ALLEGRO OPHTHALMICS
Allegro Ophthalmics is a late-stage ophthalmic biopharmaceutical company focused on redefining the retina space with integrin inhibition therapy, a potential market-disrupting class of drugs for the treatment of retinal diseases. Allegro’s lead investigational drug, risuteganib (Luminate), a broad-spectrum integrin inhibitor, downregulates oxidative stress upstream, at its source, simultaneously affecting all four pathways of oxidative stress that contribute to retinal diseases such as diabeti... c macular edema (DME) and nonexudative age-related macular degeneration (dry AMD). Risuteganib has successfully met the endpoints for three Phase 2 studies and is preparing to enter Phase 3 studies in DME during the first half of 2019. In addition, risuteganib is being studied in a Phase 2 trial for the treatment of dry AMD with topline results anticipated in Q3 2019. Allegro is working closely with the global retina community to bring to market new treatment options for leading causes of blindness and is committed to offering patients an improved quality of life sustained by self-sufficient, functional vision.
ALLEGRO OPHTHALMICS
Industry:
Biotechnology Pharmaceutical
Founded:
2011-01-01
Address:
San Juan Capistrano, California, United States
Country:
United States
Website Url:
http://www.allegroeye.com
Total Employee:
11+
Status:
Active
Contact:
+9499408130
Email Addresses:
[email protected]
Total Funding:
42.7 M USD
Technology used in webpage:
Domain Not Resolving Person Schema Gravatar Profiles U.S. Server Location
Similar Organizations
Acceleron Pharma
Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
MabVax Therapeutics
MabVax is a biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Viatris
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Hanmi Pharmaceutical
Hanmi Pharmaceutical investment in Series C - Allegro Ophthalmics
Official Site Inspections
http://www.allegroeye.com Semrush global rank: 5.44 M Semrush visits lastest month: 1.37 K
- Host name: 137.68.167.72.host.secureserver.net
- IP address: 72.167.68.137
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Allegro Ophthalmics"
About Us - Allegro Ophthalmics - From Theory to Therapy
Allegro Ophthalmics is establishing integrin peptide therapy as the next-generation pharmaceutical category for the treatment of neovascular retinal diseases. Our lead …See details»
Allegro Ophthalmics, LLC | LinkedIn
Allegro Ophthalmics, LLC is a late-stage ophthalmic biopharmaceutical company focused on redefining the retina space with integrin inhibition therapy, a potential market-disrupting class …See details»
Allegro Ophthalmics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +9499408130 Allegro Ophthalmics is a late-stage ophthalmic biopharmaceutical company focused on redefining the retina space with …See details»
Allegro Ophthalmics, LLC Information - RocketReach
Allegroeye.com; aol.com; 4 949235XXXX; 949489XXXX; 949489XXXX; 949940XXXX; John Park Co-Founder and Vice President at Allegro Ophthalmics, LLC Santa Ana, CA, US View. 1 …See details»
Allegro Ophthalmics - Craft
Allegro Ophthalmics has 5 employees at their 1 location and $42.7 m in total funding,. See insights on Allegro Ophthalmics including office locations, competitors, revenue, financials, …See details»
Allegro Ophthalmics - The Org
Allegro Ophthalmics, LLC is a late-stage ophthalmic biopharmaceutical company focused on redefining the retina space with integrin inhibition therapy, a potential market-disrupting class …See details»
Allegro Ophthalmics - 2025 Company Profile & Funding - Tracxn
Apr 25, 2025 Allegro Ophthalmics - New therapies to retain their vision of people living with diabetes and age-related macular degeneration. Raised a total funding of $48.2M over 8 …See details»
Management Team - Allegroeye
The commercial success of any therapy depends not just on the science but on the people who bring these innovative treatments to market. Our talented, passionate management team …See details»
Allegro Ophthalmics - Overview, News & Similar companies
Allegro Ophthalmics contact info: Phone number: (949) 940-8130 Website: www.allegroeye.com What does Allegro Ophthalmics do? Allegro Ophthalmics, LLC is a privately held …See details»
Allegro Ophthalmics - Phone, Email, Employees, CEO, VP, 2024
Description. With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to delivering and establishing Integrin Peptide Therapy TM …See details»
Allegro Ophthalmics, LLC - Overview, Competitors, And ... - Ampliz
Allegro Ophthalmics, LLC`s Overview, Revenue, Employee Size, Location For Free. Find Key Decision Makers Of Allegro Ophthalmics, LLC Email, Phone, LinkedIn Profile.See details»
Company - Allegro Ophthalmics - From Theory to Therapy
Apr 13, 2023 We’re bringing innovation to the eye care space with a novel mitochondrial stabilizer therapy, a new class of drugs for the treatment of ocular diseases. Risuteganib …See details»
Allegro Ophthalmics LLC (Allegro Ophthalmics LLC) - 药物管线_专 …
Mar 8, 2025 - Intermediate Dry AMD Treatment Is a Significant Unmet Need - Mitochondrial Stabilizing Candidate Risuteganib Has Shown Best Corrected Visual Acuity Gains in Dry AMD …See details»
Allegro Ophthalmics - VentureRadar
Auto Analyst Score: 62 | allegroeye.com. VentureRadar Popularity. Medium. VentureRadar Popularity: Medium. The popularity score combines profile views, clicks and the number of …See details»
Allegro Ophthalmics | CipherBio
Explore Allegro Ophthalmics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Home - Allegro Ophthalmics - From Theory to Therapy
Email: [email protected]. RECENT NEWS. Allegro Ophthalmics Licensee AffaMed Therapeutics Receives Phase 3 CTA Approval in China for Risuteganib for the Treatment of …See details»
Bausch Health To Acquire Option To Purchase All Ophthalmology …
Sep 21, 2020 For more information, visit www.allegroeye.com. About Bausch + Lomb Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely …See details»
Management Team - Allegro Ophthalmics - From Theory to Therapy
Sep 25, 2023 The commercial success of any therapy depends not just on the science but on the people who bring these innovative treatments to market. Our talented, passionate …See details»
Pipeline - Allegro Ophthalmics - From Theory to Therapy
Email: [email protected]. RECENT NEWS. Allegro Ophthalmics Licensee AffaMed Therapeutics Receives Phase 3 CTA Approval in China for Risuteganib for the Treatment of …See details»
Board of Directors - Allegro Ophthalmics - From Theory to Therapy
These seasoned professionals bring a strong foundation of integrity and a wealth of experience in ophthalmology to Allegro. From research and development to manufacturing to corporate …See details»